All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
During the ASCO 2021 Annual Meeting, the Multiple Myeloma Hub spoke with Maria Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We asked, what are the outcomes of triple-class exposed/refractory disease in real-world care: What is the current SoC?
Outcomes of triple-class exposed/refractory disease in real-world care: What is the current SoC?
Mateos discusses the results from LocoMMotion (NCT04035226), the first prospective efficacy and safety study of real-life SOC in patients with relapsed/refractory multiple myeloma (RRMM).
Once-weekly dosing of carfilzomib approved by FDA
The FDA has approved a once-weekly dosing regimen of carfilzomib in combination with dexamethasone
Educational theme | Monoclonal antibodies for the treatment of multiple myeloma
As the next educational theme, the Multiple Myeloma Hub will be evaluating the ongoing potential of mAb-based therapies for the treatment of MM.
Subscribe to get the best content related to multiple myeloma delivered to your inbox